Most recently, Puig et al. demonstrated that upregulation of the epigenetic modification enzyme TET2 and its catalytic product 5hmC are biomarkers of slow–cycling cancer cell, a cell in dormancy state with chemoresistance, in different cancer types. Here, TET2 is linked to cancer.